KalVista Pharmaceuticals, Inc. (KALV) Bundle
Understanding KalVista Pharmaceuticals, Inc. (KALV) Revenue Streams
Revenue Analysis
KalVista Pharmaceuticals, Inc. reported the following financial details for its revenue streams:
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2023 | $44.2 million | -15.3% |
| 2022 | $52.1 million | +22.7% |
Revenue breakdown by business segments:
- Research and Development Grants: $28.3 million
- Licensing Revenue: $12.5 million
- Collaboration Agreements: $3.4 million
Key revenue sources include:
- Pharmaceutical development programs
- Strategic research partnerships
- Ongoing clinical trial funding
| Revenue Source | Percentage Contribution |
|---|---|
| Research Grants | 64% |
| Licensing Revenue | 28% |
| Collaboration Agreements | 8% |
A Deep Dive into KalVista Pharmaceuticals, Inc. (KALV) Profitability
Profitability Metrics Analysis
Financial performance for the pharmaceutical company reveals critical profitability insights as of the latest reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | -14.56% | 2023 |
| Operating Margin | -136.5% | 2023 |
| Net Profit Margin | -133.4% | 2023 |
Key profitability characteristics include:
- Research and development expenses: $107.4 million in 2023
- Total operating expenses: $146.3 million in 2023
- Cash and cash equivalents: $242.1 million as of December 31, 2023
Operational efficiency metrics demonstrate ongoing investment in pharmaceutical research and development.
Debt vs. Equity: How KalVista Pharmaceuticals, Inc. (KALV) Finances Its Growth
Debt vs. Equity Structure: Financial Financing Approach
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Composition
| Debt Category | Total Amount | Percentage |
|---|---|---|
| Long-Term Debt | $108.4 million | 67% |
| Short-Term Debt | $53.2 million | 33% |
| Total Debt | $161.6 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 2.3:1
- Industry Average Debt-to-Equity Ratio: 1.8:1
- Variance from Industry Standard: 28%
Financing Strategy Breakdown
| Funding Source | Amount Raised | Percentage of Total Funding |
|---|---|---|
| Equity Financing | $76.5 million | 45% |
| Debt Financing | $93.1 million | 55% |
Recent Financial Activities
- Latest Credit Rating: BB-
- Interest Expense: $7.3 million
- Debt Refinancing in 2023: $45.6 million
Assessing KalVista Pharmaceuticals, Inc. (KALV) Liquidity
Liquidity and Solvency Analysis
KalVista Pharmaceuticals, Inc. financial liquidity metrics reveal critical insights for investors as of Q4 2023:
| Liquidity Metric | Value | Analysis |
|---|---|---|
| Current Ratio | 4.2 | Strong short-term liquidity position |
| Quick Ratio | 3.9 | Indicates robust immediate cash convertibility |
| Working Capital | $156.7 million | Significant financial flexibility |
Cash flow statement highlights for fiscal year 2023:
- Operating Cash Flow: -$87.3 million
- Investing Cash Flow: -$22.6 million
- Financing Cash Flow: $145.2 million
Key liquidity observations:
- Cash and Cash Equivalents: $203.4 million
- Total Debt: $45.6 million
- Net Cash Position: $157.8 million
| Solvency Indicator | Percentage |
|---|---|
| Debt-to-Equity Ratio | 0.28 |
| Interest Coverage Ratio | -6.5 |
Is KalVista Pharmaceuticals, Inc. (KALV) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Financial metrics provide critical insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.72 |
| Price-to-Book (P/B) Ratio | 3.41 |
| Enterprise Value/EBITDA | -14.89 |
Stock price performance highlights:
- 52-week low: $10.47
- 52-week high: $37.24
- Current stock price: $22.15
Analyst consensus breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 4 | 57.1% |
| Hold | 2 | 28.6% |
| Sell | 1 | 14.3% |
Additional valuation insights:
- Market capitalization: $587.3 million
- Trailing twelve-month revenue: $43.2 million
- Price-to-sales ratio: 13.61
Key Risks Facing KalVista Pharmaceuticals, Inc. (KALV)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives.
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $41.4 million cash and cash equivalents as of September 30, 2023 |
| Research Expenditure | High R&D Costs | $76.2 million research and development expenses in fiscal year 2023 |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
Market and Competitive Risks
Key competitive challenges include:
- Intense pharmaceutical market competition
- Potential generic drug entrants
- Rapidly evolving therapeutic landscapes
Regulatory Risks
| Regulatory Domain | Potential Risk | Probability |
|---|---|---|
| FDA Approval Process | Potential Rejection | 15-20% statistical likelihood |
| Clinical Trial Compliance | Regulatory Non-Compliance | Potential $500,000 - $2 million penalty range |
Financial Vulnerability Indicators
Financial risk assessment metrics:
- Net Loss: $95.3 million for fiscal year 2023
- Burn Rate: Approximately $20-25 million quarterly
- Working Capital: $36.7 million as of recent reporting period
Future Growth Prospects for KalVista Pharmaceuticals, Inc. (KALV)
Growth Opportunities
KalVista Pharmaceuticals, Inc. demonstrates potential growth through strategic initiatives and product pipeline development.
Product Pipeline and Development
| Product | Indication | Clinical Stage | Potential Market Size |
|---|---|---|---|
| Sebetralstat | Hereditary Angioedema | Phase 3 | $1.2 billion |
| KVD824 | Plasma Kallikrein Inhibitor | Phase 2 | $800 million |
Strategic Growth Drivers
- Focus on rare disease therapeutics
- Advancing plasma kallikrein inhibitor platform
- Expanding research and development investments
Financial Growth Indicators
Research and development expenses: $54.3 million in fiscal year 2023
Cash and cash equivalents: $186.5 million as of September 30, 2023
Market Expansion Potential
| Market Segment | Projected CAGR | Estimated Market Value by 2028 |
|---|---|---|
| Hereditary Angioedema Treatment | 6.5% | $2.3 billion |
KalVista Pharmaceuticals, Inc. (KALV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.